nodes	percent_of_prediction	percent_of_DWPC	metapath
Rimonabant—CYP1A2—Imiquimod—skin cancer	0.158	0.188	CbGbCtD
Rimonabant—CYP2C9—Vismodegib—skin cancer	0.0984	0.118	CbGbCtD
Rimonabant—CYP1A2—Vemurafenib—skin cancer	0.0863	0.103	CbGbCtD
Rimonabant—CYP3A4—Temozolomide—skin cancer	0.0826	0.0987	CbGbCtD
Rimonabant—CYP3A4—Imiquimod—skin cancer	0.0826	0.0987	CbGbCtD
Rimonabant—CYP2D6—Vemurafenib—skin cancer	0.0711	0.085	CbGbCtD
Rimonabant—CYP1A2—Dacarbazine—skin cancer	0.0662	0.0791	CbGbCtD
Rimonabant—CYP3A4—Vismodegib—skin cancer	0.0572	0.0684	CbGbCtD
Rimonabant—CYP3A4—Vemurafenib—skin cancer	0.0452	0.0541	CbGbCtD
Rimonabant—CYP1A2—Fluorouracil—skin cancer	0.0388	0.0464	CbGbCtD
Rimonabant—CYP2C9—Fluorouracil—skin cancer	0.035	0.0418	CbGbCtD
Rimonabant—CYP3A4—Docetaxel—skin cancer	0.0155	0.0186	CbGbCtD
Rimonabant—Memory loss—Fluorouracil—skin cancer	0.00449	0.0296	CcSEcCtD
Rimonabant—Connective tissue disorder—Vismodegib—skin cancer	0.00224	0.0148	CcSEcCtD
Rimonabant—Malnutrition—Vismodegib—skin cancer	0.00198	0.0131	CcSEcCtD
Rimonabant—Aggression—Bleomycin—skin cancer	0.00193	0.0127	CcSEcCtD
Rimonabant—CNR2—Small Ligand GPCRs—PTGER4—skin cancer	0.00191	0.162	CbGpPWpGaD
Rimonabant—Muscle spasms—Vismodegib—skin cancer	0.00191	0.0126	CcSEcCtD
Rimonabant—Lethargy—Imiquimod—skin cancer	0.00177	0.0117	CcSEcCtD
Rimonabant—Unspecified disorder of skin and subcutaneous tissue—Vismodegib—skin cancer	0.00168	0.0111	CcSEcCtD
Rimonabant—Irritability—Imiquimod—skin cancer	0.00166	0.0109	CcSEcCtD
Rimonabant—Disturbance in attention—Temozolomide—skin cancer	0.00165	0.0109	CcSEcCtD
Rimonabant—Nervous system disorder—Vismodegib—skin cancer	0.00159	0.0105	CcSEcCtD
Rimonabant—Skin disorder—Vismodegib—skin cancer	0.00157	0.0104	CcSEcCtD
Rimonabant—Infestation NOS—Vemurafenib—skin cancer	0.00157	0.0103	CcSEcCtD
Rimonabant—Infestation—Vemurafenib—skin cancer	0.00157	0.0103	CcSEcCtD
Rimonabant—Influenza—Imiquimod—skin cancer	0.0015	0.00989	CcSEcCtD
Rimonabant—CNR1—Small Ligand GPCRs—PTGER4—skin cancer	0.0015	0.127	CbGpPWpGaD
Rimonabant—Decreased appetite—Vismodegib—skin cancer	0.00141	0.00928	CcSEcCtD
Rimonabant—Gastrointestinal disorder—Vismodegib—skin cancer	0.0014	0.00922	CcSEcCtD
Rimonabant—Fatigue—Vismodegib—skin cancer	0.0014	0.0092	CcSEcCtD
Rimonabant—Upper respiratory tract infection—Imiquimod—skin cancer	0.00139	0.00919	CcSEcCtD
Rimonabant—Connective tissue disorder—Vemurafenib—skin cancer	0.00138	0.00912	CcSEcCtD
Rimonabant—Infestation NOS—Imiquimod—skin cancer	0.00134	0.00882	CcSEcCtD
Rimonabant—Infestation—Imiquimod—skin cancer	0.00134	0.00882	CcSEcCtD
Rimonabant—Depression—Imiquimod—skin cancer	0.00133	0.00879	CcSEcCtD
Rimonabant—Gastrointestinal pain—Vismodegib—skin cancer	0.00132	0.00873	CcSEcCtD
Rimonabant—Abdominal pain—Vismodegib—skin cancer	0.00128	0.00844	CcSEcCtD
Rimonabant—Angiopathy—Vemurafenib—skin cancer	0.00128	0.00842	CcSEcCtD
Rimonabant—Mediastinal disorder—Vemurafenib—skin cancer	0.00127	0.00837	CcSEcCtD
Rimonabant—Sinusitis—Imiquimod—skin cancer	0.00125	0.00827	CcSEcCtD
Rimonabant—Malnutrition—Vemurafenib—skin cancer	0.00123	0.00808	CcSEcCtD
Rimonabant—Connective tissue disorder—Imiquimod—skin cancer	0.00118	0.00778	CcSEcCtD
Rimonabant—Lethargy—Dactinomycin—skin cancer	0.00117	0.00774	CcSEcCtD
Rimonabant—Gastroenteritis—Temozolomide—skin cancer	0.00117	0.00774	CcSEcCtD
Rimonabant—Asthenia—Vismodegib—skin cancer	0.00116	0.00766	CcSEcCtD
Rimonabant—Pruritus—Vismodegib—skin cancer	0.00115	0.00755	CcSEcCtD
Rimonabant—Hot flush—Temozolomide—skin cancer	0.00111	0.00733	CcSEcCtD
Rimonabant—Diarrhoea—Vismodegib—skin cancer	0.00111	0.0073	CcSEcCtD
Rimonabant—Amnesia—Temozolomide—skin cancer	0.00111	0.0073	CcSEcCtD
Rimonabant—Menopausal symptoms—Temozolomide—skin cancer	0.0011	0.00727	CcSEcCtD
Rimonabant—Angiopathy—Imiquimod—skin cancer	0.00109	0.00718	CcSEcCtD
Rimonabant—Mediastinal disorder—Imiquimod—skin cancer	0.00108	0.00713	CcSEcCtD
Rimonabant—Mental disorder—Imiquimod—skin cancer	0.00105	0.00693	CcSEcCtD
Rimonabant—Malnutrition—Imiquimod—skin cancer	0.00105	0.00689	CcSEcCtD
Rimonabant—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—skin cancer	0.00104	0.00683	CcSEcCtD
Rimonabant—Vomiting—Vismodegib—skin cancer	0.00103	0.00679	CcSEcCtD
Rimonabant—Rash—Vismodegib—skin cancer	0.00102	0.00673	CcSEcCtD
Rimonabant—Amnesia—Fluorouracil—skin cancer	0.00102	0.00672	CcSEcCtD
Rimonabant—Dermatitis—Vismodegib—skin cancer	0.00102	0.00672	CcSEcCtD
Rimonabant—Infection—Vemurafenib—skin cancer	0.000994	0.00655	CcSEcCtD
Rimonabant—Mood swings—Temozolomide—skin cancer	0.000985	0.0065	CcSEcCtD
Rimonabant—Nervous system disorder—Vemurafenib—skin cancer	0.000981	0.00647	CcSEcCtD
Rimonabant—Lethargy—Fluorouracil—skin cancer	0.000978	0.00645	CcSEcCtD
Rimonabant—Skin disorder—Vemurafenib—skin cancer	0.000971	0.00641	CcSEcCtD
Rimonabant—Nausea—Vismodegib—skin cancer	0.000962	0.00634	CcSEcCtD
Rimonabant—Irritability—Fluorouracil—skin cancer	0.000915	0.00603	CcSEcCtD
Rimonabant—Convulsion—Imiquimod—skin cancer	0.000905	0.00597	CcSEcCtD
Rimonabant—Anxiety—Imiquimod—skin cancer	0.000887	0.00585	CcSEcCtD
Rimonabant—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.000884	0.00583	CcSEcCtD
Rimonabant—Dry mouth—Imiquimod—skin cancer	0.00087	0.00574	CcSEcCtD
Rimonabant—Decreased appetite—Vemurafenib—skin cancer	0.000869	0.00573	CcSEcCtD
Rimonabant—Gastrointestinal disorder—Vemurafenib—skin cancer	0.000863	0.00569	CcSEcCtD
Rimonabant—Fatigue—Vemurafenib—skin cancer	0.000862	0.00569	CcSEcCtD
Rimonabant—Hypoaesthesia—Bleomycin—skin cancer	0.000849	0.0056	CcSEcCtD
Rimonabant—Infection—Imiquimod—skin cancer	0.000847	0.00559	CcSEcCtD
Rimonabant—Nervous system disorder—Imiquimod—skin cancer	0.000836	0.00552	CcSEcCtD
Rimonabant—Upper respiratory tract infection—Temozolomide—skin cancer	0.000835	0.00551	CcSEcCtD
Rimonabant—Skin disorder—Imiquimod—skin cancer	0.000828	0.00546	CcSEcCtD
Rimonabant—Hyperhidrosis—Imiquimod—skin cancer	0.000825	0.00544	CcSEcCtD
Rimonabant—Anorexia—Imiquimod—skin cancer	0.000813	0.00536	CcSEcCtD
Rimonabant—Infestation NOS—Temozolomide—skin cancer	0.000801	0.00528	CcSEcCtD
Rimonabant—Infestation—Temozolomide—skin cancer	0.000801	0.00528	CcSEcCtD
Rimonabant—Depression—Temozolomide—skin cancer	0.000799	0.00527	CcSEcCtD
Rimonabant—Insomnia—Imiquimod—skin cancer	0.000771	0.00509	CcSEcCtD
Rimonabant—Upper respiratory tract infection—Fluorouracil—skin cancer	0.00077	0.00507	CcSEcCtD
Rimonabant—Paraesthesia—Imiquimod—skin cancer	0.000766	0.00505	CcSEcCtD
Rimonabant—Sinusitis—Temozolomide—skin cancer	0.000752	0.00496	CcSEcCtD
Rimonabant—Decreased appetite—Imiquimod—skin cancer	0.000741	0.00489	CcSEcCtD
Rimonabant—Hot flush—Docetaxel—skin cancer	0.000739	0.00487	CcSEcCtD
Rimonabant—Infestation NOS—Fluorouracil—skin cancer	0.000738	0.00487	CcSEcCtD
Rimonabant—Infestation—Fluorouracil—skin cancer	0.000738	0.00487	CcSEcCtD
Rimonabant—Gastrointestinal disorder—Imiquimod—skin cancer	0.000736	0.00486	CcSEcCtD
Rimonabant—Fatigue—Imiquimod—skin cancer	0.000735	0.00485	CcSEcCtD
Rimonabant—Menopausal symptoms—Docetaxel—skin cancer	0.000733	0.00483	CcSEcCtD
Rimonabant—Asthenia—Vemurafenib—skin cancer	0.000718	0.00473	CcSEcCtD
Rimonabant—Hypoaesthesia—Temozolomide—skin cancer	0.000716	0.00472	CcSEcCtD
Rimonabant—Hallucination—Temozolomide—skin cancer	0.000716	0.00472	CcSEcCtD
Rimonabant—Pruritus—Vemurafenib—skin cancer	0.000708	0.00467	CcSEcCtD
Rimonabant—Connective tissue disorder—Temozolomide—skin cancer	0.000707	0.00466	CcSEcCtD
Rimonabant—Lethargy—Docetaxel—skin cancer	0.000706	0.00465	CcSEcCtD
Rimonabant—Gastrointestinal pain—Imiquimod—skin cancer	0.000697	0.0046	CcSEcCtD
Rimonabant—Sinusitis—Fluorouracil—skin cancer	0.000693	0.00457	CcSEcCtD
Rimonabant—Diarrhoea—Vemurafenib—skin cancer	0.000684	0.00451	CcSEcCtD
Rimonabant—Abdominal pain—Imiquimod—skin cancer	0.000674	0.00445	CcSEcCtD
Rimonabant—Dizziness—Vemurafenib—skin cancer	0.000661	0.00436	CcSEcCtD
Rimonabant—Hypoaesthesia—Fluorouracil—skin cancer	0.00066	0.00435	CcSEcCtD
Rimonabant—Angiopathy—Temozolomide—skin cancer	0.000653	0.0043	CcSEcCtD
Rimonabant—Mediastinal disorder—Temozolomide—skin cancer	0.000648	0.00428	CcSEcCtD
Rimonabant—Vomiting—Vemurafenib—skin cancer	0.000636	0.00419	CcSEcCtD
Rimonabant—Rash—Vemurafenib—skin cancer	0.000631	0.00416	CcSEcCtD
Rimonabant—Mental disorder—Temozolomide—skin cancer	0.00063	0.00416	CcSEcCtD
Rimonabant—Dermatitis—Vemurafenib—skin cancer	0.00063	0.00415	CcSEcCtD
Rimonabant—Headache—Vemurafenib—skin cancer	0.000627	0.00413	CcSEcCtD
Rimonabant—Malnutrition—Temozolomide—skin cancer	0.000626	0.00413	CcSEcCtD
Rimonabant—Cramp muscle—Docetaxel—skin cancer	0.000623	0.00411	CcSEcCtD
Rimonabant—Asthenia—Imiquimod—skin cancer	0.000612	0.00403	CcSEcCtD
Rimonabant—Pruritus—Imiquimod—skin cancer	0.000603	0.00398	CcSEcCtD
Rimonabant—Infection—Bleomycin—skin cancer	0.000602	0.00397	CcSEcCtD
Rimonabant—Nausea—Vemurafenib—skin cancer	0.000594	0.00392	CcSEcCtD
Rimonabant—Tremor—Temozolomide—skin cancer	0.000587	0.00387	CcSEcCtD
Rimonabant—Diarrhoea—Imiquimod—skin cancer	0.000584	0.00385	CcSEcCtD
Rimonabant—Anorexia—Bleomycin—skin cancer	0.000578	0.00381	CcSEcCtD
Rimonabant—Dizziness—Imiquimod—skin cancer	0.000564	0.00372	CcSEcCtD
Rimonabant—Infection—Dactinomycin—skin cancer	0.000561	0.0037	CcSEcCtD
Rimonabant—Paraesthesia—Bleomycin—skin cancer	0.000544	0.00359	CcSEcCtD
Rimonabant—Convulsion—Temozolomide—skin cancer	0.000543	0.00358	CcSEcCtD
Rimonabant—Vomiting—Imiquimod—skin cancer	0.000542	0.00358	CcSEcCtD
Rimonabant—Anorexia—Dactinomycin—skin cancer	0.000539	0.00355	CcSEcCtD
Rimonabant—Rash—Imiquimod—skin cancer	0.000538	0.00355	CcSEcCtD
Rimonabant—Dermatitis—Imiquimod—skin cancer	0.000537	0.00354	CcSEcCtD
Rimonabant—Headache—Imiquimod—skin cancer	0.000534	0.00352	CcSEcCtD
Rimonabant—Infestation NOS—Docetaxel—skin cancer	0.000533	0.00351	CcSEcCtD
Rimonabant—Infestation—Docetaxel—skin cancer	0.000533	0.00351	CcSEcCtD
Rimonabant—Anxiety—Temozolomide—skin cancer	0.000531	0.0035	CcSEcCtD
Rimonabant—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.00053	0.00349	CcSEcCtD
Rimonabant—Decreased appetite—Bleomycin—skin cancer	0.000527	0.00347	CcSEcCtD
Rimonabant—Dry mouth—Temozolomide—skin cancer	0.000521	0.00344	CcSEcCtD
Rimonabant—Infection—Temozolomide—skin cancer	0.000508	0.00335	CcSEcCtD
Rimonabant—Nausea—Imiquimod—skin cancer	0.000507	0.00334	CcSEcCtD
Rimonabant—Nervous system disorder—Temozolomide—skin cancer	0.000501	0.00331	CcSEcCtD
Rimonabant—Convulsion—Fluorouracil—skin cancer	0.0005	0.0033	CcSEcCtD
Rimonabant—Skin disorder—Temozolomide—skin cancer	0.000496	0.00327	CcSEcCtD
Rimonabant—Hyperhidrosis—Temozolomide—skin cancer	0.000494	0.00326	CcSEcCtD
Rimonabant—Decreased appetite—Dactinomycin—skin cancer	0.000491	0.00324	CcSEcCtD
Rimonabant—Fatigue—Dactinomycin—skin cancer	0.000487	0.00321	CcSEcCtD
Rimonabant—Anorexia—Temozolomide—skin cancer	0.000487	0.00321	CcSEcCtD
Rimonabant—Hypoaesthesia—Docetaxel—skin cancer	0.000476	0.00314	CcSEcCtD
Rimonabant—Connective tissue disorder—Docetaxel—skin cancer	0.00047	0.0031	CcSEcCtD
Rimonabant—Infection—Fluorouracil—skin cancer	0.000468	0.00308	CcSEcCtD
Rimonabant—Insomnia—Temozolomide—skin cancer	0.000462	0.00305	CcSEcCtD
Rimonabant—Gastrointestinal pain—Dactinomycin—skin cancer	0.000462	0.00305	CcSEcCtD
Rimonabant—Nervous system disorder—Fluorouracil—skin cancer	0.000462	0.00305	CcSEcCtD
Rimonabant—Paraesthesia—Temozolomide—skin cancer	0.000459	0.00303	CcSEcCtD
Rimonabant—Anorexia—Fluorouracil—skin cancer	0.000449	0.00296	CcSEcCtD
Rimonabant—Abdominal pain—Dactinomycin—skin cancer	0.000447	0.00295	CcSEcCtD
Rimonabant—Decreased appetite—Temozolomide—skin cancer	0.000444	0.00293	CcSEcCtD
Rimonabant—Gastrointestinal disorder—Temozolomide—skin cancer	0.000441	0.00291	CcSEcCtD
Rimonabant—Fatigue—Temozolomide—skin cancer	0.000441	0.00291	CcSEcCtD
Rimonabant—CNR1—GPCRs, Other—SMO—skin cancer	0.00044	0.0372	CbGpPWpGaD
Rimonabant—Asthenia—Bleomycin—skin cancer	0.000435	0.00287	CcSEcCtD
Rimonabant—Angiopathy—Docetaxel—skin cancer	0.000434	0.00286	CcSEcCtD
Rimonabant—Mediastinal disorder—Docetaxel—skin cancer	0.000431	0.00284	CcSEcCtD
Rimonabant—Pruritus—Bleomycin—skin cancer	0.000429	0.00283	CcSEcCtD
Rimonabant—Insomnia—Fluorouracil—skin cancer	0.000426	0.00281	CcSEcCtD
Rimonabant—Paraesthesia—Fluorouracil—skin cancer	0.000423	0.00279	CcSEcCtD
Rimonabant—Mental disorder—Docetaxel—skin cancer	0.000419	0.00276	CcSEcCtD
Rimonabant—Gastrointestinal pain—Temozolomide—skin cancer	0.000418	0.00276	CcSEcCtD
Rimonabant—Malnutrition—Docetaxel—skin cancer	0.000416	0.00275	CcSEcCtD
Rimonabant—Decreased appetite—Fluorouracil—skin cancer	0.000409	0.0027	CcSEcCtD
Rimonabant—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000407	0.00268	CcSEcCtD
Rimonabant—Asthenia—Dactinomycin—skin cancer	0.000405	0.00267	CcSEcCtD
Rimonabant—Abdominal pain—Temozolomide—skin cancer	0.000404	0.00266	CcSEcCtD
Rimonabant—Muscle spasms—Docetaxel—skin cancer	0.0004	0.00264	CcSEcCtD
Rimonabant—Diarrhoea—Dactinomycin—skin cancer	0.000387	0.00255	CcSEcCtD
Rimonabant—Vomiting—Bleomycin—skin cancer	0.000385	0.00254	CcSEcCtD
Rimonabant—Rash—Bleomycin—skin cancer	0.000382	0.00252	CcSEcCtD
Rimonabant—Dermatitis—Bleomycin—skin cancer	0.000382	0.00252	CcSEcCtD
Rimonabant—Asthenia—Temozolomide—skin cancer	0.000367	0.00242	CcSEcCtD
Rimonabant—Pruritus—Temozolomide—skin cancer	0.000362	0.00238	CcSEcCtD
Rimonabant—Convulsion—Docetaxel—skin cancer	0.000361	0.00238	CcSEcCtD
Rimonabant—CNR2—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.000361	0.0305	CbGpPWpGaD
Rimonabant—Nausea—Bleomycin—skin cancer	0.00036	0.00237	CcSEcCtD
Rimonabant—Vomiting—Dactinomycin—skin cancer	0.000359	0.00237	CcSEcCtD
Rimonabant—Rash—Dactinomycin—skin cancer	0.000356	0.00235	CcSEcCtD
Rimonabant—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000352	0.00232	CcSEcCtD
Rimonabant—Diarrhoea—Temozolomide—skin cancer	0.00035	0.00231	CcSEcCtD
Rimonabant—Dry mouth—Docetaxel—skin cancer	0.000347	0.00229	CcSEcCtD
Rimonabant—Dizziness—Temozolomide—skin cancer	0.000338	0.00223	CcSEcCtD
Rimonabant—Infection—Docetaxel—skin cancer	0.000338	0.00223	CcSEcCtD
Rimonabant—Nausea—Dactinomycin—skin cancer	0.000336	0.00221	CcSEcCtD
Rimonabant—Nervous system disorder—Docetaxel—skin cancer	0.000333	0.0022	CcSEcCtD
Rimonabant—Pruritus—Fluorouracil—skin cancer	0.000333	0.0022	CcSEcCtD
Rimonabant—Skin disorder—Docetaxel—skin cancer	0.00033	0.00218	CcSEcCtD
Rimonabant—CNR2—GPCR ligand binding—PTCH2—skin cancer	0.000325	0.0275	CbGpPWpGaD
Rimonabant—Vomiting—Temozolomide—skin cancer	0.000325	0.00214	CcSEcCtD
Rimonabant—Anorexia—Docetaxel—skin cancer	0.000324	0.00214	CcSEcCtD
Rimonabant—Rash—Temozolomide—skin cancer	0.000322	0.00212	CcSEcCtD
Rimonabant—Diarrhoea—Fluorouracil—skin cancer	0.000322	0.00212	CcSEcCtD
Rimonabant—Dermatitis—Temozolomide—skin cancer	0.000322	0.00212	CcSEcCtD
Rimonabant—Headache—Temozolomide—skin cancer	0.00032	0.00211	CcSEcCtD
Rimonabant—Dizziness—Fluorouracil—skin cancer	0.000311	0.00205	CcSEcCtD
Rimonabant—CNR2—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.000309	0.0262	CbGpPWpGaD
Rimonabant—Insomnia—Docetaxel—skin cancer	0.000307	0.00203	CcSEcCtD
Rimonabant—Paraesthesia—Docetaxel—skin cancer	0.000305	0.00201	CcSEcCtD
Rimonabant—Nausea—Temozolomide—skin cancer	0.000304	0.002	CcSEcCtD
Rimonabant—Vomiting—Fluorouracil—skin cancer	0.000299	0.00197	CcSEcCtD
Rimonabant—Rash—Fluorouracil—skin cancer	0.000297	0.00196	CcSEcCtD
Rimonabant—Dermatitis—Fluorouracil—skin cancer	0.000297	0.00196	CcSEcCtD
Rimonabant—Decreased appetite—Docetaxel—skin cancer	0.000295	0.00195	CcSEcCtD
Rimonabant—Headache—Fluorouracil—skin cancer	0.000295	0.00195	CcSEcCtD
Rimonabant—Gastrointestinal disorder—Docetaxel—skin cancer	0.000293	0.00193	CcSEcCtD
Rimonabant—Fatigue—Docetaxel—skin cancer	0.000293	0.00193	CcSEcCtD
Rimonabant—CNR1—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.000283	0.024	CbGpPWpGaD
Rimonabant—Nausea—Fluorouracil—skin cancer	0.00028	0.00184	CcSEcCtD
Rimonabant—Gastrointestinal pain—Docetaxel—skin cancer	0.000278	0.00183	CcSEcCtD
Rimonabant—Abdominal pain—Docetaxel—skin cancer	0.000269	0.00177	CcSEcCtD
Rimonabant—CNR1—GPCR ligand binding—PTCH2—skin cancer	0.000255	0.0216	CbGpPWpGaD
Rimonabant—Asthenia—Docetaxel—skin cancer	0.000244	0.00161	CcSEcCtD
Rimonabant—CNR1—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.000242	0.0205	CbGpPWpGaD
Rimonabant—Pruritus—Docetaxel—skin cancer	0.00024	0.00159	CcSEcCtD
Rimonabant—CNR2—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.000237	0.0201	CbGpPWpGaD
Rimonabant—CNR2—GPCR ligand binding—MC1R—skin cancer	0.000235	0.0199	CbGpPWpGaD
Rimonabant—Diarrhoea—Docetaxel—skin cancer	0.000233	0.00153	CcSEcCtD
Rimonabant—Dizziness—Docetaxel—skin cancer	0.000225	0.00148	CcSEcCtD
Rimonabant—Vomiting—Docetaxel—skin cancer	0.000216	0.00143	CcSEcCtD
Rimonabant—Rash—Docetaxel—skin cancer	0.000214	0.00141	CcSEcCtD
Rimonabant—Dermatitis—Docetaxel—skin cancer	0.000214	0.00141	CcSEcCtD
Rimonabant—Headache—Docetaxel—skin cancer	0.000213	0.0014	CcSEcCtD
Rimonabant—CNR2—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.000203	0.0172	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—RHOU—skin cancer	0.000202	0.0171	CbGpPWpGaD
Rimonabant—Nausea—Docetaxel—skin cancer	0.000202	0.00133	CcSEcCtD
Rimonabant—CNR1—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.000186	0.0158	CbGpPWpGaD
Rimonabant—CNR1—GPCR ligand binding—MC1R—skin cancer	0.000185	0.0156	CbGpPWpGaD
Rimonabant—CNR2—GPCR ligand binding—SHH—skin cancer	0.000168	0.0142	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—PTCH2—skin cancer	0.000167	0.0141	CbGpPWpGaD
Rimonabant—CNR1—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.000159	0.0135	CbGpPWpGaD
Rimonabant—CNR2—GPCR ligand binding—PTCH1—skin cancer	0.000159	0.0135	CbGpPWpGaD
Rimonabant—CNR2—GPCR ligand binding—SMO—skin cancer	0.000159	0.0135	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—RHOU—skin cancer	0.000159	0.0134	CbGpPWpGaD
Rimonabant—CNR2—GPCR ligand binding—PTGER4—skin cancer	0.000155	0.0131	CbGpPWpGaD
Rimonabant—CNR2—GPCR downstream signaling—MC1R—skin cancer	0.000133	0.0113	CbGpPWpGaD
Rimonabant—CNR1—GPCR ligand binding—SHH—skin cancer	0.000132	0.0111	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—PTCH2—skin cancer	0.000131	0.0111	CbGpPWpGaD
Rimonabant—CNR1—GPCR ligand binding—SMO—skin cancer	0.000125	0.0106	CbGpPWpGaD
Rimonabant—CNR1—GPCR ligand binding—PTCH1—skin cancer	0.000125	0.0106	CbGpPWpGaD
Rimonabant—CNR1—GPCR ligand binding—PTGER4—skin cancer	0.000121	0.0103	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—MC1R—skin cancer	0.000121	0.0102	CbGpPWpGaD
Rimonabant—CNR1—GPCR downstream signaling—MC1R—skin cancer	0.000104	0.00883	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—PTCH2—skin cancer	9.87e-05	0.00835	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—MC1R—skin cancer	9.47e-05	0.00802	CbGpPWpGaD
Rimonabant—CNR2—GPCR downstream signaling—PTGER4—skin cancer	8.74e-05	0.0074	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—SHH—skin cancer	8.6e-05	0.00728	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—SMO—skin cancer	8.16e-05	0.0069	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—PTCH1—skin cancer	8.16e-05	0.0069	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—PTGER4—skin cancer	7.94e-05	0.00672	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—PTCH2—skin cancer	7.74e-05	0.00655	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—GLI2—skin cancer	7.48e-05	0.00633	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—MC1R—skin cancer	7.13e-05	0.00604	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—GLI1—skin cancer	7.03e-05	0.00595	CbGpPWpGaD
Rimonabant—CNR1—GPCR downstream signaling—PTGER4—skin cancer	6.86e-05	0.00581	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—SHH—skin cancer	6.75e-05	0.00571	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—SUFU—skin cancer	6.66e-05	0.00564	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—PTCH1—skin cancer	6.4e-05	0.00542	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—SMO—skin cancer	6.4e-05	0.00542	CbGpPWpGaD
Rimonabant—CNR1—BDNF signaling pathway—HRAS—skin cancer	6.37e-05	0.00539	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—PTGER4—skin cancer	6.23e-05	0.00527	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—GLI2—skin cancer	5.87e-05	0.00497	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—MC1R—skin cancer	5.6e-05	0.00474	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—GLI1—skin cancer	5.52e-05	0.00467	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—SUFU—skin cancer	5.23e-05	0.00443	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—SHH—skin cancer	5.08e-05	0.0043	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—RASA1—skin cancer	5.05e-05	0.00427	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—PTCH1—skin cancer	4.82e-05	0.00408	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—SMO—skin cancer	4.82e-05	0.00408	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—PTGER4—skin cancer	4.69e-05	0.00397	CbGpPWpGaD
Rimonabant—CYP2C9—Arachidonic acid metabolism—PTGS2—skin cancer	4.22e-05	0.00357	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—FOXO4—skin cancer	4.14e-05	0.00351	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—SHH—skin cancer	3.99e-05	0.00338	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—RASA1—skin cancer	3.96e-05	0.00335	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—skin cancer	3.85e-05	0.00326	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—PTCH1—skin cancer	3.78e-05	0.0032	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—SMO—skin cancer	3.78e-05	0.0032	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—PTGER4—skin cancer	3.68e-05	0.00312	CbGpPWpGaD
Rimonabant—CYP1A2—Arachidonic acid metabolism—PTGS2—skin cancer	3.6e-05	0.00305	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—FOXO4—skin cancer	3.25e-05	0.00275	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	3.16e-05	0.00267	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—skin cancer	3e-05	0.00254	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—TERT—skin cancer	2.77e-05	0.00234	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	2.7e-05	0.00228	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—skin cancer	2.58e-05	0.00218	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—NRAS—skin cancer	2.33e-05	0.00197	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—skin cancer	2.19e-05	0.00186	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—BRAF—skin cancer	2.19e-05	0.00185	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—TERT—skin cancer	2.17e-05	0.00184	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—KRAS—skin cancer	2.01e-05	0.0017	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—NRAS—skin cancer	1.83e-05	0.00155	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—BRAF—skin cancer	1.72e-05	0.00146	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—HRAS—skin cancer	1.71e-05	0.00144	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—IL6—skin cancer	1.63e-05	0.00138	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—KRAS—skin cancer	1.57e-05	0.00133	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—PLIN2—skin cancer	1.42e-05	0.0012	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—PLIN2—skin cancer	1.41e-05	0.00119	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—NRAS—skin cancer	1.38e-05	0.00117	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—HRAS—skin cancer	1.34e-05	0.00113	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—IL6—skin cancer	1.28e-05	0.00108	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—PLIN2—skin cancer	1.2e-05	0.00102	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—KRAS—skin cancer	1.19e-05	0.001	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—CSPG4—skin cancer	1.14e-05	0.000968	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—CSPG4—skin cancer	1.13e-05	0.00096	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—NRAS—skin cancer	1.08e-05	0.000915	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—TP53—skin cancer	1.05e-05	0.000892	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—HRAS—skin cancer	1.01e-05	0.000853	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—CSPG4—skin cancer	9.69e-06	0.00082	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—IL6—skin cancer	9.64e-06	0.000816	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—KRAS—skin cancer	9.3e-06	0.000787	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—PLIN2—skin cancer	9.28e-06	0.000785	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—TP53—skin cancer	8.27e-06	0.0007	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—HRAS—skin cancer	7.91e-06	0.000669	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—ENO2—skin cancer	7.77e-06	0.000658	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—ENO2—skin cancer	7.71e-06	0.000652	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—IL6—skin cancer	7.57e-06	0.000641	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—CSPG4—skin cancer	7.48e-06	0.000633	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—ENO2—skin cancer	6.59e-06	0.000557	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	6.03e-06	0.00051	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	5.15e-06	0.000436	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—ENO2—skin cancer	5.08e-06	0.00043	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—ERCC2—skin cancer	4.52e-06	0.000382	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—ERCC2—skin cancer	4.48e-06	0.000379	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—ERCC2—skin cancer	3.83e-06	0.000324	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—ERCC2—skin cancer	2.95e-06	0.00025	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—PTGS2—skin cancer	2.71e-06	0.000229	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—PTGS2—skin cancer	2.68e-06	0.000227	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—PTGS2—skin cancer	2.29e-06	0.000194	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—PTGS2—skin cancer	1.77e-06	0.00015	CbGpPWpGaD
